Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C13H14N2O |
| Molecular Weight | 214.2631 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=C2C=CC=CC2=NC3=C1C(O)CCC3
InChI
InChIKey=HLVVITIHAZBPKB-UHFFFAOYSA-N
InChI=1S/C13H14N2O/c14-13-8-4-1-2-5-9(8)15-10-6-3-7-11(16)12(10)13/h1-2,4-5,11,16H,3,6-7H2,(H2,14,15)
Velnacrine (9-amino-1,2,3,4-tetrahydroacridin-1-ol) is an inhibitor of acetylcholinesterase. It was studied for the treatment of Alzheimer's disease however development was discontinued. There has been no research into the use of velnacrine as a cognitive enhancer in the treatment of Alzheimer's disease since 1994. The FDA peripheral and CNS drug advisory board voted unanimously against recommending approval. This review shows the toxic nature of velnacrine, and provides no evidence of efficacy.
Originator
Approval Year
Sample Use Guides
Velnacrine for the treatment of Alzheimer's disease (a double-blind, placebo-controlled trials): 10, 25, 50 and 75 mg t.i.d. The 225 mg/day dose appears to be safe for use in multicenter outpatient trials of velnacrine efficacy in Alzheimer's disease.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47792
Created by
admin on Fri Dec 15 17:27:14 GMT 2023 , Edited by admin on Fri Dec 15 17:27:14 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL51934
Created by
admin on Fri Dec 15 17:27:14 GMT 2023 , Edited by admin on Fri Dec 15 17:27:14 GMT 2023
|
PRIMARY | |||
|
m983
Created by
admin on Fri Dec 15 17:27:14 GMT 2023 , Edited by admin on Fri Dec 15 17:27:14 GMT 2023
|
PRIMARY | Merck Index | ||
|
104675-29-8
Created by
admin on Fri Dec 15 17:27:14 GMT 2023 , Edited by admin on Fri Dec 15 17:27:14 GMT 2023
|
SUPERSEDED | |||
|
3655
Created by
admin on Fri Dec 15 17:27:14 GMT 2023 , Edited by admin on Fri Dec 15 17:27:14 GMT 2023
|
PRIMARY | |||
|
C056424
Created by
admin on Fri Dec 15 17:27:14 GMT 2023 , Edited by admin on Fri Dec 15 17:27:14 GMT 2023
|
PRIMARY | |||
|
Y2P6NV151K
Created by
admin on Fri Dec 15 17:27:14 GMT 2023 , Edited by admin on Fri Dec 15 17:27:14 GMT 2023
|
PRIMARY | |||
|
100000079097
Created by
admin on Fri Dec 15 17:27:14 GMT 2023 , Edited by admin on Fri Dec 15 17:27:14 GMT 2023
|
PRIMARY | |||
|
6403
Created by
admin on Fri Dec 15 17:27:14 GMT 2023 , Edited by admin on Fri Dec 15 17:27:14 GMT 2023
|
PRIMARY | |||
|
SUB00033MIG
Created by
admin on Fri Dec 15 17:27:14 GMT 2023 , Edited by admin on Fri Dec 15 17:27:14 GMT 2023
|
PRIMARY | |||
|
DTXSID4046945
Created by
admin on Fri Dec 15 17:27:14 GMT 2023 , Edited by admin on Fri Dec 15 17:27:14 GMT 2023
|
PRIMARY | |||
|
3848
Created by
admin on Fri Dec 15 17:27:14 GMT 2023 , Edited by admin on Fri Dec 15 17:27:14 GMT 2023
|
PRIMARY | |||
|
124027-47-0
Created by
admin on Fri Dec 15 17:27:14 GMT 2023 , Edited by admin on Fri Dec 15 17:27:14 GMT 2023
|
PRIMARY | |||
|
C96773
Created by
admin on Fri Dec 15 17:27:14 GMT 2023 , Edited by admin on Fri Dec 15 17:27:14 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
